CD19 and neoplasm: Next, to explore whether the incorporation of aIL6 scFv would affect the anti-tumor activity of CART cells, we inoculated NCG mice with GFP-expressing Nalm6 cells and treated them with anti-CD19 CART-aIL6/Fc, which demonstrated efficient eradication of GFP+ tumor cells and long term survival as compared to anti-CD19 CART/Fc (Fig. 1d).